Immunosuppressive properties of methotrexate: Apoptosis and clonal deletion of activated peripheral T cells

Journal of Clinical Investigation

Volumn 102, Issue 2, 1998, Pages 322-328

  Genestier, Laurent ^a   Paillot, Romain ^a   Fournel, Sylvie ^a   Ferraro, Carole ^a   Miossec, Pierre ^b   Revillard, Jean Pierre ^a,b  

^a UNIVERSITÉ LYON 1   (France)

^b EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

Apoptosis; Methotrexate; Rheumatoid arthritis; T lymphocytes; Thymidylate synthase

Indexed keywords

METHOTREXATE;

ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; CHRONIC INFLAMMATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; MIXED LYMPHOCYTE REACTION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; T LYMPHOCYTE ACTIVATION;

EID: 0032528186     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI2676     Document Type: Article

References (39)

1. Farber, S., R. Toch, E. Manning Sears, and D. Pinkel. 1956. Advances in chemotherapy of cancer in man. In Advances in Cancer Research. H.A. Greenstein J.-P., editor. Academic Press, New York. 2-73.
2. Weinblatt, M.E., J.S. Coblyn, D.A. Fox, P.A. Fraser, D.E. Holdsworth, D.N. Glass, and D.E. Trentham. 1985. Efficacy of low-dose methotrexate in rheumatoid arthritis. N. Engl. J. Med. 312:818-822.
3. Williams, H.J., R.F. Wilkens, C.O. Samuelson, G.S. Alarcon, M. Guttadauria, C. Yarboro, R.P. Polisson, S.R. Weiner, M.E. Luggen, L.M. Billingsley, et al. 1985. Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis: a controlled clinical trial. Arthritis Rheum. 28:721-730.
4. Slorb, R., H.J. Deeg, J. Whitehead, F. Appelbaum, P. Beatty, W. Bensinger, D. Buckner, R. Clift, K. Doney, V. Farewell, et al. 1986. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft-versus-host disease after marrow transplantation for leukemia. N. Engl. J. Med. 314:729-735.
5. Nash, R.A., M.S. Pepe, R. Storb, G. Longton, M. Pettinger, C. Anasetti, F.R. Appelbaum, R.A. Bowden, H.J. Deeg, K. Doney, et al. 1992. Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. Blood. 80:1838-1845.
6. Chao, N.J., G.M. Schmidt, J.C. Niland, M.D. Amylon, A.C. Dagis, G.D. Long, A.P. Nademanee, R.S. Negrin, M.R. O'Donnell, P.M. Parker, et al. 1993. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease. N. Engl. J. Med. 329:1225-1230.
7. Nash, R.A., L.A. Pineiro, R. Storb, J.H. Deeg, W.E. Fitzsimmon, T. Furlong, J.A. Hansen, T. Gooley, R.M. Maher, P. Martin, et al. 1996. FK506 combination with methotrexate for the prevention of graft-versus-host disease after marrow transplantation from matched unrelated donors. Blood. 88:3634-3641.
8. Olsen, S.L., J.B. O'Connell, M.R. Bristow, and D.G. Renlund. 1990. Methotrexate as an adjunct in the treatment of persistent mild cardiac allograft rejection. Transplantation. 50:773-775.
9. Jolivet, J., R.L. Schilsky, B.D. Bailey, J.C. Drake, and B.A. Chabner. 1982. Synthesis, retention, and biological activity of methotrexate polyglutamates in cultured human breast cancer cells. J. Clin. Invest. 70:351-360.
10. Jolivet, J., and B.A. Chabner. 1983. Intracellular pharmacokinetics of methotrexate polyglutamates in human breast cancer cells. J. Clin. Invest. 72: 773-778.
11. Chabner, P.A., C.J. Allegra, G.A. Curt, N.J. Clendeninn, J. Baram, S. Koisumi, J.C. Drake, and J. Jolivet. 1985. Polyglutamation of methotrexate. Is methotrexate a prodrug? J. Clin. Invest. 76:907-912.
12. Allegra, C.J., J.C. Drake, J. Jolivet, and B.A. Chabner. 1985. Inhibition of phosphoribosyl-aminoimidazole-carboxamide transformylase by methotrexale and dihydrofolic acid polyglutamates. Proc. Natl. Acad. Sci. USA. 82:4881-4885.
13. Vincent C., S. Fournel, J. Widjenes, and J.P. Revillard. 1995. Specific hyporesponsiveness of alloreactive peripheral T cells induced by CD4 antibodies. Eur. J. Immunol. 25:816-822.
14. Fournel, S., L. Genestier, J.-P. Rouault, G. Lizard, M. Flacher, O. Assossou, and J.-P. Revillard. 1995. Apoptosis without decrease of cell DNA content. FEBS Lett. 367:188-192.
15. Koupman, G., C. Reutelingsperger, G. Kuijten, R. Keehnen, S. Pals, and M. Van Oers. 1994. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood. 84:1415-1420.
16. Gorczyca, W., J. Gong, and Z. Darzynkiewicz. 1993. Detection of DNA strand breaks in indvidual apoptotic cells by the in situ terminal deoxynucleotidyl transferase and nick translation assays. Cancer Res. 53:1945-1951.
17. Benhamou, L.E., P.A. Cazenave, and P. Sarthou. 1990. Anti-immunoglobulins induce death by apoptosis in WEHI-231 B lymphoma cells. Eur. J. Immunol. 20:1405-1407.
18. Zamzami, N., P. Marchetti, M. Castedo, C. Zanin, J.-L. Vayssière, P.X. Petit, and G. Kroemer. 1995. Reduction in mitochondrial potential constitutes an early irreversible step of programmed lymphocyte death in vivo. J. Exp. Med. 181:1661-1672.
19. Fournel, S., E. Robinet, N. Bonnefoy-Bérard, O. Assossou, M. Flacher, H. Waldmann, G. Bismuth, J.-P. Revillard. 1998. A noncomitogenic CD2R monoclonal antibody induces apoptosis of activated T cells by a CD95/CD95-L-dependent pathway. J. Immunol. 160: 4313-4321.
20. Rieux-Laucat, F., F. Le Deist, C. Hivroz, I.A.G. Roberts, K.M. Debatin, A. Fischer, and J.P. de Villartay. 1995. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science. 268:1347-1349.
21. Cronstein, B.N., D. Naime, and E. Ostad. 1993. The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J. Clin. Invest. 92:2675-2682.
22. Friesen, C., I. Herr, P.H. Krammer, and K.-M. Debatin. 1996. Involvement of the CD95 (APO-1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat. Med. 2:574-577.
23. Fournel, S., L. Genestier, E. Robinet, M. Flacher, and J.-P. Revillard. 1996. Human T cells require IL-2 but not G1/S transition to acquire susceptibility to Fas-mediated apoptosis. J. Immunol. 157:4309-4315.
24. Singer, A., and F. Bach. 1995. Allograft immunity: in vitro and in vivo studies. In Transplantation Immunology. F. Bach and H. Auchincloss, editors. Wiley-Liss, New York. 105-111.
25. Cronstein, B.N., E.D. Rosenstein, S.B. Kramer, G. Weissmann, and R. Hirschhorn. 1985. Adenosine: a physiologic modulator of superoxide anion generation by human neutrophils. Adenosine acts via an A2 receptor on human neutrophils. J. Immunol. 135:1366-1371.
26. Cronstein, B.N., R.I. Levin, J. Belanoff, G. Weissmann, and R. Hirschhorn. 1986. Adenosine: an endogenous inhibitor of neutrophil-mediated injury to endothelial cells. J. Clin. Invest. 78:760-770.
27. Cronstein, B.N., M.A. Eberle, H.E. Gruber, and R.I. Levin. 1991. Methotrexate inhibits neutrophil function by stimulating adenosine release from connective tissue cells. Proc. Natl. Acad. Sci. USA. 88:2441-2445.
28. Morabito, L., M.C. Montesinos, D.M. Schreibman, L. Balter, L.F. Thompson, R. Resta, G. Carlin, M.A. Huie, B.N. Cronstein. 1998. Methotrexate and sulfasalazine promote adenosine release by a mechanism that requires ecto-5-nucleotidase-mediated conversion of adenosine nucleotides. J. Clin. Invest. 101:295-300.
29. Cronstein, B.N., and R. Hirschhorn. 1990. Adenosine and host defense. In Adenosine and Adenosine Receptors. M. Williams, editor. The Human Press, Clifton, NJ. 475-500.
30. Sonneveld, P., F. Schultz, K. Nooter, and K. Hahlen. 1986. Pharmacokinetics of methotrexate and 7-hydroxy-methotrexate in plasma and bone marrow of children receiving low-dose oral methotrexate. Cancer Chemother. Pharmacol. 18:111-116.
31. Wallace, C., W. Bleyer, D. Sherry, D. Salmonson, and R. Wedgewood. 1989. Toxicity and serum levels of methotrexate in children with juvenile rheumatoid arthritis. Arthritis Rheum. 32:677-681.
32. Sinnett, M., G. Groff, D. Raddatz, W. Franck, and J. Bertino. 1989. Methotrexate pharmacokinetics in patients with rheumatoid arthritis. J. Rheumatol. 16:745-748.
33. Lowe, S.W., H.E. Ruley, T. Jacks, and D.E. Housman. 1993. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 74:957-967.
34. Fisher, D.E. 1994. Apoptosis in cancer therapy: crossing the threshold. Cell. 78:539-542.
35. Almasan, A., Y. Yin, R.E. Kelly, E. Lee, A. Bradley, W. Li, J. Bertino, and G. Wahl. 1995. Deficiency of retinoblastoma protein leads to inappropriate S-phase entry, activation of E2F-responsive genes, and apoptosis. Proc. Natl. Acad. Sci. USA. 92:5436-5440.
36. Müller, M., S. Strand, H. Hug, E.-M. Heinemann, H. Walczak, W. Hofmann, W. Stremmel, P. Krammer, and P. Galle. 1997. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J. Clin. Invest. 99:403-413.
37. Genestier, L., R. Paillot, N. Bonnefoy-Bérard, G. Meffre, M. Flacher, D. Fèvre, Y.J. Liu, P. Le Bouteiller, H. Waldmann, V.H. Engelhard, J. Banchereau, and J.-P. Revillard. 1997. Fas-independent apoptosis of activated T cells induced by antibodies to the HLA class I α1 domain. Blood. 90:3629-3639.
38. Brugnoni, D., P. Airo, F. Facchetti, L. Blanzuoli, A.G. Ugazio, R. Cattaneo, and L.D. Notarangelo. 1997. In vitro death of activated lymphocytes in Omenn's syndrome. Eur. J. Immunol. 27:2765-2773.
39. De Maria, R., M. Boirivant, M.G. Cifone, P. Roncaioli, M. Hahne, J. Tschopp, F. Pallone, A. Santoni, and R. Testi. 1996. Functional expression of Fas and Fas ligand on human gut lamina propria T lymphocytes. A potential role for the acidic sphingomyelinase pathway in normal immunoregulation. J. Clin. Invest. 97:316-322.